AAAAI Annual Meeting 2026: key results and trends

In the primary analysis, benralizumab-treated patients (n=67) experienced a reduced risk of HES flare compared to placebo-treated patients (n=66); HR (95% CI): 0.35 (0.18–0.69); P=0.0024.

The proportion of patients experiencing ≥1 treatment-emergent adverse event was 69.7% with dupilumab vs 78.6% placebo.

Patient incidence of TEAEs (patients receiving at least one dose of study drug; 128 ROCA, 68 PBO): ROCA, 41.4% vs PBO, 30.9%; serious AEs, 2.3% vs 0.0%.

In integrated analysis, participants on depemokimab and placebo reported similar incidences of on-treatment adverse events (68% [23/34] vs. 86% [25/29]) and serious adverse events (3% [1/34] vs. 14% [4/29]).

Three of four (75%) patients reported TEAEs, none of which were severe, serious, related to donidalorsen, or led to treatment discontinuation.

At week 24, bezuclastinib led to significantly greater symptom improvement vs placebo (LS mean MS2D2 TSS change: -24.3 vs -15.4; placebo-adjusted difference: -8.9 points; P =0.0002).

Significant improvement in itch with APG777 was observed as early as Day 3, with a mean -18.1% change from baseline in I-NRS (vs. -4.2% placebo; p<0.01), which improved through Week 16 (-50.7% vs -23.2%; p=0.001).

Briquilimab treatment resulted in durable disease control in CSU patients, with 8 of 11 participants (73%) achieving complete response in UAS7 at the Week 12 assessment.

Subjects who completed the full year of treatment with STMC-103H demonstrated a 64% reduction in the risk of developing AD compared to placebo (23.3% vs 43.1%; OR = 0.36; 90% CI 0.20-0.66; unadjusted p = 0.005) at D336.

Treatment-emergent adverse events (TEAEs) were reported by 63.6%, 73.2% and 90.7% subjects in the BP11, EU-Omalizumab, and US-Omalizumab groups, respectively.